How Minerva Simplifies Clinical Trials Operations in Pakistan

What Do Clinical Trials Operations in Pakistan Actually Involve?

You might assume “trial operations” just means running the study day to day. In practice, it starts well before the first patient is enrolled and continues long after the last visit.

Research shows that around 80% of clinical trials fail to meet their initial patient-enrollment targets, which is exactly the kind of gap good operations management is meant to close. At Minerva Research Solutions, clinical trials operations cover the full arc of a study, not isolated pieces of it:

• Feasibility review and site selection.
• Regulatory and ethics submissions.
• Site activation and staff training.
• Patient recruitment and retention.
• Ongoing monitoring and safety reporting.
• Data management and final close-out.

Each of these connects to the next. A rushed site selection shows up later as a recruitment problem. A weak clinical research workflow at the start surfaces as a data problem near the end. Treating operations as one continuous process, rather than a checklist, is what keeps a study on schedule.

The Guide to Conduct Clinical Research in Pakistan: The DRAP Pathway

Pakistan’s clinical trials are regulated by the Drug Regulatory Authority of Pakistan (DRAP) under the Bio-Study Rules, 2017, through its Clinical Studies Committee within the Division of Pharmacy Services. As of 2026, Pakistan has 33 DRAP-registered CROs and 53 certified trial hospitals supporting the sector. DRAP has also published its own guide to conduct clinical research in Pakistan, laying out submission requirements and documentation applicants need at each stage.

For sponsors, the practical takeaway is that ethics and regulatory approval are not one-off events. They are an ongoing relationship managed carefully from first submission through closure. This is where Minerva’s regulatory team stays involved throughout, tracking query deadlines and keeping DRAP and IRB correspondence moving instead of leaving sponsors to chase updates themselves.

Why Getting the Regulatory Sequence Right Saves Time Later:

Sponsors sometimes treat regulatory approval as a box to check before the “real” work starts. That mindset backfires. Incomplete or inconsistently documented submissions come back with queries, and every query adds weeks. Running submissions in parallel with early site preparation is what keeps operations moving instead of stalling at the start.

Mapping the Clinical Research Workflow: From Site Selection to Close-Out

You might be wondering what this actually looks like stage by stage. It is easiest to understand as a sequence of connected stages, not a single event. Here is roughly how it plays out:

None of these stages work well in isolation. A site activated too fast, without proper training, generates errors that only show up once monitoring or data review begins. Following the sequence carefully, rather than skipping ahead, keeps the whole clinical research workflow predictable.

Minerva Research Solutions runs this as one continuous handoff rather than separate contracts per stage, so the team managing site activation is the same one accountable for what shows up in the data phase.

What Clinical Trial Support Services Keep Operations on Track?

Here is the thing sponsors coming into Pakistan for the first time often underestimate: it is not just about having a site willing to participate. It is about the coordination clinical trial support services provide behind the scenes to keep every part of the trial moving at the same pace.

The clinical trial support services that tend to matter most day to day include:

• Site management — training, logistics, and ongoing support so sites stay audit-ready.
• Patient recruitment and retention — outreach and engagement that keeps enrollment on schedule.
• Monitoring and quality assurance — regular site visits and documentation review against GCP requirements.
• Pharmacovigilance — adverse event tracking and timely safety reporting.
• Regulatory liaison — staying in contact with DRAP and IRBs as the study progresses.

When these run as separate, disconnected services, sponsors end up doing the coordination work themselves. Minerva runs them under one process instead, with a single point of contact per study, so that burden shifts off the sponsor’s plate rather than adding a sixth vendor relationship to manage.

Why Clinical Study Management Depends on Clean Data

Here is the thing about clinical study management: the science can be sound, the sites can run smoothly, and the study can still fall apart if the data behind it is messy. It depends on information being handled correctly from day one, not cleaned up afterward.

Pakistan’s clinical research footprint is still small relative to its potential. Every trial that runs cleanly strengthens the country’s case for a bigger share of global research volume.

Good clinical study management means:

• Designing databases that are organized and query-ready from the start.
• Cleaning data continuously, not just before submission.
• Running statistical analysis that produces results regulators can actually rely on.
• Reporting findings in the format authorities expect.

A trial can have excellent recruitment and well-trained sites and still run into trouble if the underlying data is inconsistent. That is why data management and biostatistics sit at the center of Minerva’s approach, not off to the side.

How U.S. Trial Experience Strengthens Local Operations

It is worth asking why U.S. clinical trial experience matters for a study running in Pakistan. The short answer is that international sponsors evaluating a research partner are, whether they say it outright or not, comparing that partner against the standards they already know.

It does not mean a Pakistani trial has to look identical to one run in the U.S. It means the discipline behind documentation, timelines, and query handling carries over, giving sponsors a confidence a purely local track record might not.

How Minerva Simplifies It in Practice

Put together, this is what “simplifying operations” actually means at Minerva: sponsors do not manage five separate vendor relationships across regulatory, site, recruitment, data, and safety work. One team carries the study from feasibility through close-out, which means a regulatory delay gets flagged to the site team the same day, not discovered weeks later on a status call, and a data query traces back to a person who was on the ground when it happened.

Minerva Research Solutions runs site management, regulatory and ethics submissions, patient recruitment, monitoring and quality assurance, pharmacovigilance, and data management and biostatistics under one accountable process, with a single point of contact per study. Our team works across multiple cities in Pakistan, pairing DRAP-licensed local expertise with the operational discipline built through U.S. trial experience, so sponsors get coordination built into the process instead of something they have to manage themselves.

Conclusion

Clinical trials operations in Pakistan work best when every stage, from regulatory submission to final data lock, is treated as one connected process rather than separate tasks handed to separate vendors. Regulatory alignment, a disciplined clinical research workflow, dependable clinical trial support services, and careful clinical study management all have to move together.

Sponsors evaluating a research partner tend to notice this quickly. It shows up in how smoothly the first few weeks of a study go, long before results are anywhere in sight.